Bildkälla: Stockfoto

BB Biotech: Historical premium to NAV no longer present - SEB

BB Biotech's shares, which historically have traded at a double-digit premium relative to the net asset value of its underlying investment portfolio, now is priced in line with its NAV. When this has happened in the past, the premium has quickly rebounded.

BB Biotech's shares, which historically have traded at a double-digit premium relative to the net asset value of its underlying investment portfolio, now is priced in line with its NAV. When this has happened in the past, the premium has quickly rebounded.
Börsvärldens nyhetsbrev
ANNONSER